Sabrina Gozlan-Kelner
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Mosquito-borne diseases and control, Malaria Research and Control, Retinal Diseases and Treatments, Mitochondrial Function and Pathology, COVID-19 epidemiological studies
Most-Cited Works
- → Inhibition of Oxygen-Induced Retinopathy in RTP801-Deficient Mice(2004)128 cited
- → A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults(2022)32 cited
- → 636. A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Quadrivalent Dengue Vaccine (V181)(2021)